Market Overview:
The global integrin beta 3 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of various diseases, such as melanoma, arterial thrombosis, diabetic macular edema (DME), and lung cancer. In addition, the increasing demand for novel therapeutics is also contributing to the growth of this market. Based on type, the global integrin beta 3 market can be segmented into MSP-68, OCU-200, AC-301 C-16Y and others. The MSP-68 segment is expected to account for a major share of this market in 2018. This segment is anticipated to grow at a high rate during the forecast period owing to its high efficacy in treating various diseases. Based on application, the global integrin beta 3 market can be divided into melanoma DME,, arterial thrombosis,, lung cancer and others segments. The melanoma segment accounted for a major share of this market in 2017 and is projected to maintain its dominance duringthe forecast period owingtoits high prevalenceand growing awareness about early diagnosis and treatment options available for this disease .
Product Definition:
Integrin beta 3 is a protein that helps cells attach to their surroundings. It is important for the development of new blood vessels and for the growth and spread of cancer cells.
MSP-68:
Integrin beta 3 (ITGB3) is a protein that belongs to the family of integrin receptors. It is also known as vascular endothelial growth factor receptor 2 (VEGFR2). The primary function of Integrin Beta 3 is to regulate blood flow in response to hypoxia or increased oxygen demand.
OCU-200:
OCU-200 is a novel small molecule inhibitor of integrin beta 3. It has shown potent anti-inflammatory activity in vitro and in vivo, with EC50 values ranging from 0.1 to 1 ?M. The compound has also shown inhibitory effects on neutrophil adhesion and chemotaxis activities, as well as monocyte rolling along the endothelial surface.
Application Insights:
The other application segment includes the Integrin beta 3 market by type in cancer, cardiovascular diseases, diabetic retinopathy, glaucoma and ocular hypertension. The use ofIntegrins has been found to be beneficial in various ophthalmic disorders such as diabetic retinopathy and glaucoma. Thus, this factor is anticipated to create growth opportunities for the global market over the forecast period.
The melanoma segment held a significant share of the overall revenue in 2017 owing to its high prevalence rate globally coupled with ongoing research activities regarding new drug development for treating different types of malignant tumors including melanoma.
Regional Analysis:
North America Integrin Beta 3 Market dominated the global arena in 2017. This can be attributed to the presence of a large number of key players, high investment in R&D and increasing prevalence of cancer & diabetes. The region is expected to maintain its dominance over the forecast period due to continuous efforts by major companies for commercialization of products with improved efficacy and enhanced safety as compared to existing products.
Asia Pacific Integrin Beta 3 market is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare infrastructure & availability of effective treatment methods along with growing awareness regarding early diagnosis among patients. Moreover, government initiatives such as “One Health†concept are also expected favorably impact regional market growth during the projected time frame.
In addition, increasing investments by governments for development.
Growth Factors:
- Increasing prevalence of chronic diseases such as cancer, arthritis, and cardiovascular diseases is expected to drive the demand for integrin beta 3 inhibitors over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth owing to increasing incidence of age-related disorders such as cancer and arthritis.
- Rising awareness about benefits offered by integrin beta 3 inhibitors in treatment of various chronic diseases is projected to propel the demand for these drugs in coming years.
- Technological advancements in drug discovery and development are likely to provide lucrative opportunities for market players over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Integrin Beta 3 Market Research Report
By Type
MSP-68, OCU-200, AC-301, C-16Y, Others
By Application
Melanoma, Arterial Thrombosis, Diabetic Macular Edema, Lung Cancer, Others
By Companies
Factor Therapeutics Ltd, Merck & Co Inc, SciFluor Life Sciences LLC, SOM Biotech SL, Vascular Pharmaceuticals Inc, VDDI Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Integrin Beta 3 Market Report Segments:
The global Integrin Beta 3 market is segmented on the basis of:
Types
MSP-68, OCU-200, AC-301, C-16Y, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Melanoma, Arterial Thrombosis, Diabetic Macular Edema, Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Factor Therapeutics Ltd
- Merck & Co Inc
- SciFluor Life Sciences LLC
- SOM Biotech SL
- Vascular Pharmaceuticals Inc
- VDDI Pharmaceuticals
Highlights of The Integrin Beta 3 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- MSP-68
- OCU-200
- AC-301
- C-16Y
- Others
- By Application:
- Melanoma
- Arterial Thrombosis
- Diabetic Macular Edema
- Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Integrin Beta 3 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Integrin beta 3 is a protein that helps cells attach to other cells. It also helps the body move materials around inside and outside of cells.
Some of the major companies in the integrin beta 3 market are Factor Therapeutics Ltd, Merck & Co Inc, SciFluor Life Sciences LLC, SOM Biotech SL, Vascular Pharmaceuticals Inc, VDDI Pharmaceuticals.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Integrin Beta 3 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Integrin Beta 3 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Integrin Beta 3 Market - Supply Chain
4.5. Global Integrin Beta 3 Market Forecast
4.5.1. Integrin Beta 3 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Integrin Beta 3 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Integrin Beta 3 Market Absolute $ Opportunity
5. Global Integrin Beta 3 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Integrin Beta 3 Market Size and Volume Forecast by Type
5.3.1. MSP-68
5.3.2. OCU-200
5.3.3. AC-301
5.3.4. C-16Y
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Integrin Beta 3 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Integrin Beta 3 Market Size and Volume Forecast by Application
6.3.1. Melanoma
6.3.2. Arterial Thrombosis
6.3.3. Diabetic Macular Edema
6.3.4. Lung Cancer
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Integrin Beta 3 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Integrin Beta 3 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Integrin Beta 3 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Integrin Beta 3 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Integrin Beta 3 Demand Share Forecast, 2019-2026
9. North America Integrin Beta 3 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Integrin Beta 3 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Integrin Beta 3 Market Size and Volume Forecast by Application
9.4.1. Melanoma
9.4.2. Arterial Thrombosis
9.4.3. Diabetic Macular Edema
9.4.4. Lung Cancer
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Integrin Beta 3 Market Size and Volume Forecast by Type
9.7.1. MSP-68
9.7.2. OCU-200
9.7.3. AC-301
9.7.4. C-16Y
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Integrin Beta 3 Demand Share Forecast, 2019-2026
10. Latin America Integrin Beta 3 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Integrin Beta 3 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Integrin Beta 3 Market Size and Volume Forecast by Application
10.4.1. Melanoma
10.4.2. Arterial Thrombosis
10.4.3. Diabetic Macular Edema
10.4.4. Lung Cancer
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Integrin Beta 3 Market Size and Volume Forecast by Type
10.7.1. MSP-68
10.7.2. OCU-200
10.7.3. AC-301
10.7.4. C-16Y
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Integrin Beta 3 Demand Share Forecast, 2019-2026
11. Europe Integrin Beta 3 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Integrin Beta 3 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Integrin Beta 3 Market Size and Volume Forecast by Application
11.4.1. Melanoma
11.4.2. Arterial Thrombosis
11.4.3. Diabetic Macular Edema
11.4.4. Lung Cancer
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Integrin Beta 3 Market Size and Volume Forecast by Type
11.7.1. MSP-68
11.7.2. OCU-200
11.7.3. AC-301
11.7.4. C-16Y
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. -o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Integrin Beta 3 Demand Share, 2019-2026
12. Asia Pacific Integrin Beta 3 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Integrin Beta 3 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Integrin Beta 3 Market Size and Volume Forecast by Application
12.4.1. Melanoma
12.4.2. Arterial Thrombosis
12.4.3. Diabetic Macular Edema
12.4.4. Lung Cancer
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Integrin Beta 3 Market Size and Volume Forecast by Type
12.7.1. MSP-68
12.7.2. OCU-200
12.7.3. AC-301
12.7.4. C-16Y
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Integrin Beta 3 Demand Share, 2019-2026
13. Middle East & Africa Integrin Beta 3 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Integrin Beta 3 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Integrin Beta 3 Market Size and Volume Forecast by Application
13.4.1. Melanoma
13.4.2. Arterial Thrombosis
13.4.3. Diabetic Macular Edema
13.4.4. Lung Cancer
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Integrin Beta 3 Market Size and Volume Forecast by Type
13.7.1. MSP-68
13.7.2. OCU-200
13.7.3. AC-301
13.7.4. C-16Y
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Integrin Beta 3 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Integrin Beta 3 Market: Market Share Analysis
14.2. Integrin Beta 3 Distributors and Customers
14.3. Integrin Beta 3 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Factor Therapeutics Ltd
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck & Co Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. SciFluor Life Sciences LLC
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. SOM Biotech SL
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Vascular Pharmaceuticals Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. VDDI Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
